BMO Capital downgraded 4D Molecular (FDMT) to Market Perform from Outperform with a price target of $15, down from $40. 4D-150 durability in ...

Macular neovascularization within 1 year of avacincaptad pegol therapy worsens outcomes compared with patients without ...

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...

Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most ...

Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Want to know where to find the best brew near you? Stacker compiled a list of the highest-rated beers in Oregon using data ...

Soliddd, an optical and vision technology company, will debut the beta headset version of its virtual reality smart glasses ...

Some megatrends in health care are occurring that deserve our attention. We already know that as much as one-third of the U.S ...

Omega-3 polyunsaturated fatty acids and docosahexaenoic acid appear to be associated with lower age-related macular ...